326030:KRXSK Biopharmaceuticals Co., Ltd. Analysis
Data as of 2026-03-15 - not real-time
₩97,800.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Current market price (₩97,800) sits well above the DCF-derived fair value (₩46,140), suggesting the stock is priced for optimism. Yet the technical picture shows a modestly oversold condition (RSI 35.8) and a bearish MACD histogram, with the price trading below the 20‑day (₩108,500), 50‑day (₩115,148) and 200‑day (₩109,173) moving averages. Volume is on an increasing trend, providing liquidity for a potential short‑term bounce, while the 30‑day volatility of 61.8% and a beta of 0.72 indicate moderate price swings relative to the market.
Fundamentally, the company delivers robust financial health: 19.2% revenue growth, an exceptional gross margin of 93.9%, operating margin of 23.8% and ROE of 36.2%. The balance sheet is strong with cash of ₩309.5 bn versus debt of only ₩48.9 bn, and a healthy free cash flow stream. Analyst consensus (14 analysts) leans "Buy" with a median target of ₩150,000, implying a 47% upside from current levels, and the market sentiment index is in "Greed" territory (72.88).
Fundamentally, the company delivers robust financial health: 19.2% revenue growth, an exceptional gross margin of 93.9%, operating margin of 23.8% and ROE of 36.2%. The balance sheet is strong with cash of ₩309.5 bn versus debt of only ₩48.9 bn, and a healthy free cash flow stream. Analyst consensus (14 analysts) leans "Buy" with a median target of ₩150,000, implying a 47% upside from current levels, and the market sentiment index is in "Greed" territory (72.88).
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- RSI indicating oversold conditions
- Increasing volume supporting a potential bounce
- Price below all major SMAs signaling short‑term weakness
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong revenue growth and high margins
- Robust cash position with low leverage
- Analyst median target price suggesting ~47% upside
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Diverse pipeline of CNS drugs in multiple trial phases
- Sustainable cash generation and low debt-to-equity
- Strategic backing from SK Inc. providing long‑term stability
Key Metrics & Analysis
Financial Health
Revenue Growth19.20%
Profit Margin37.77%
P/E Ratio20.8
ROE36.17%
ROA11.40%
Debt/Equity5.92
Op. Cash Flow₩176.3B
Free Cash Flow₩112.0B
Industry P/E26.2
Technical Analysis
TrendNeutral
RSI35.8
Support₩95,200.00
Resistance₩119,800.00
MA 20₩108,500.00
MA 50₩115,148.00
MA 200₩109,173.00
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Fair Value₩46,140.83
Target Price₩143,785.72
Upside/Downside47.02%
GradeOvervalued
TypeBlend
Risk Assessment
Beta0.72
Volatility61.83%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.